PVG Asset Management Corp Invests $773,000 in Immuneering Corporation $IMRX

PVG Asset Management Corp acquired a new stake in Immuneering Corporation (NASDAQ:IMRX) during the 1st quarter, HoldingsChannel.com reports. The fund acquired 146,661 shares of the company’s stock, valued at approximately $773,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IMRX. Empery Asset Management LP acquired a new position in Immuneering during the 4th quarter worth $17,601,000. State Street Corp increased its holdings in Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after purchasing an additional 2,229,374 shares during the period. Vanguard Group Inc. raised its position in Immuneering by 128.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after purchasing an additional 1,358,322 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Immuneering in the 3rd quarter valued at about $6,602,000. Finally, Marshall Wace LLP boosted its stake in shares of Immuneering by 162.4% in the 4th quarter. Marshall Wace LLP now owns 711,875 shares of the company’s stock valued at $4,684,000 after buying an additional 440,571 shares during the period. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Cantor Fitzgerald initiated coverage on shares of Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target for the company. Finally, Needham & Company LLC boosted their price target on shares of Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Immuneering Price Performance

Shares of NASDAQ:IMRX opened at $4.13 on Monday. Immuneering Corporation has a 12 month low of $2.90 and a 12 month high of $10.08. The firm has a market capitalization of $267.21 million, a P/E ratio of -3.53 and a beta of 0.43. The company’s fifty day moving average price is $4.66 and its 200 day moving average price is $4.99.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. On average, sell-side analysts anticipate that Immuneering Corporation will post -1.09 EPS for the current year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.